In addition, 106 CFU MG741 improved levels of ALT and AST, known as markers of liver injury and surrogate measures of NAFLD, and reduced levels of liver triglycerides. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.